Organon (OGN) Stock Forecast, Price Target & Predictions
OGN Stock Forecast
Organon stock forecast is as follows: an average price target of $24.00 (represents a 16.79% upside from OGN’s last price of $20.55) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
OGN Price Target
The average price target for Organon (OGN) is $24.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $24.00. This represents a potential 16.79% upside from OGN's last price of $20.55.
OGN Analyst Ratings
According to 3 Wall Street analysts, Organon's rating consensus is 'Buy'. The analyst rating breakdown for OGN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Organon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 29, 2024 | David Amsellem | Piper Sandler | $24.00 | $18.84 | 27.35% | 16.79% |
| Jun 26, 2023 | David Amsellem | Piper Sandler | $34.00 | $20.36 | 66.95% | 65.45% |
The latest Organon stock forecast, released on Apr 29, 2024 by David Amsellem from Piper Sandler, set a price target of $24.00, which represents a 27.35% increase from the stock price at the time of the forecast ($18.84), and a 16.79% increase from OGN last price ($20.55).
Organon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $24.00 |
| Last Closing Price | $20.55 | $20.55 | $20.55 |
| Upside/Downside | -100.00% | -100.00% | 16.79% |
In the current month, the average price target of Organon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Organon's last price of $20.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 29, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jan 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 12, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 09, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 08, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 09, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Sep 06, 2022 | Piper Sandler | - | Overweight | Upgrade |
| Apr 27, 2022 | Goldman Sachs | - | Buy | Initialise |
| Feb 22, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Organon's last stock rating was published by Piper Sandler on Apr 29, 2024. The company gave OGN a "Overweight" rating, the same as its previous rate.
Organon Financial Forecast
Organon Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.60B | $1.52M | $1.61M | $1.54B | $1.49B | $1.54B | - | $1.57B | $1.60B | $1.60B | $1.59B | $1.51B |
| Avg Forecast | $1.57B | $1.54B | $1.62B | $1.58B | $1.60B | $1.57B | $1.61B | $1.57B | $1.55B | $1.57B | $1.57B | $1.54B | $1.49B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
| High Forecast | $1.61B | $1.57B | $1.66B | $1.62B | $1.63B | $1.58B | $1.65B | $1.60B | $1.59B | $1.60B | $1.60B | $1.58B | $1.53B | $1.55B | $1.53B | $1.56B | $1.61B | $1.62B | $1.56B | $1.61B |
| Low Forecast | $1.54B | $1.51B | $1.59B | $1.56B | $1.57B | $1.55B | $1.58B | $1.54B | $1.52B | $1.56B | $1.54B | $1.51B | $1.47B | $1.49B | $1.53B | $1.49B | $1.54B | $1.55B | $1.49B | $1.54B |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 0.00% | 0.00% | 1.00% | 0.99% | 1.02% | - | 1.03% | 1.02% | 1.01% | 1.05% | 0.96% |
Organon's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.57B, with a low forecast of $1.54B, and a high forecast of $1.60B. OGN's average Quarter revenue forecast represents a -2.05% decrease compared to the company's last Quarter revenue of $1.60B (Dec 23).
Organon EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $370.00M | $232.00K | $389.00K | $388.00M | $279.00M | $415.00M | - | $539.00M | $396.00M | $539.00M | $538.00M | $509.00M |
| Avg Forecast | $540.33M | $528.63M | $556.86M | $544.49M | $548.31M | $538.13M | $554.05M | $692.28M | $534.05M | $540.97M | $537.88M | $547.26M | $513.16M | $498.20M | $526.71M | $432.62M | $357.98M | $452.91M | $454.95M | $539.18M |
| High Forecast | $552.82M | $540.84M | $569.73M | $557.07M | $560.98M | $541.58M | $566.86M | $830.74M | $547.83M | $550.19M | $550.31M | $656.71M | $525.02M | $597.84M | $526.71M | $519.14M | $429.58M | $543.49M | $545.94M | $552.02M |
| Low Forecast | $530.61M | $519.12M | $546.84M | $534.69M | $538.44M | $531.23M | $544.08M | $553.83M | $523.71M | $535.48M | $528.20M | $437.81M | $503.93M | $398.56M | $526.71M | $346.09M | $286.39M | $362.33M | $363.96M | $528.02M |
| Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.00% | 0.00% | 0.71% | 0.54% | 0.83% | - | 1.25% | 1.11% | 1.19% | 1.18% | 0.94% |
1 analysts predict OGN's average Quarter EBITDA for Mar 24 to be $692.28M, with a high of $830.74M and a low of $553.83M. This is 87.10% upper than Organon's previous annual EBITDA (Dec 23) of $370.00M.
Organon Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $546.00M | $58.00K | $242.00K | $177.00M | $108.00M | $227.00M | - | $348.00M | $202.00M | $323.00M | $427.00M | $399.00M |
| Avg Forecast | $285.49M | $268.51M | $293.51M | $283.51M | $266.73M | $257.64M | $278.14M | $406.95M | $209.72M | $271.60M | $251.53M | $321.70M | $237.91M | $298.55M | $303.02M | $254.31M | $182.61M | $271.41M | $361.09M | $443.90M |
| High Forecast | $294.07M | $276.58M | $302.33M | $292.02M | $274.74M | $268.26M | $286.50M | $488.34M | $280.50M | $279.21M | $259.08M | $386.04M | $245.06M | $358.26M | $303.02M | $305.17M | $219.13M | $325.69M | $433.30M | $457.64M |
| Low Forecast | $278.81M | $262.23M | $286.64M | $276.88M | $260.49M | $247.02M | $271.63M | $325.56M | $178.26M | $263.98M | $245.64M | $257.36M | $232.35M | $238.84M | $303.02M | $203.45M | $146.09M | $217.13M | $288.87M | $431.95M |
| Surprise % | - | - | - | - | - | - | - | - | 2.60% | 0.00% | 0.00% | 0.55% | 0.45% | 0.76% | - | 1.37% | 1.11% | 1.19% | 1.18% | 0.90% |
Organon's average Quarter net income forecast for Mar 24 is $406.95M, with a range of $325.56M to $488.34M. OGN's average Quarter net income forecast represents a -25.47% decrease compared to the company's last Quarter net income of $546.00M (Dec 23).
Organon SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $469.00M | $538.00K | $451.00K | $435.00M | $470.00M | $440.00M | - | $371.00M | $482.00M | $388.00M | $416.00M | $382.00M |
| Avg Forecast | $388.11M | $379.70M | $399.98M | $391.10M | $393.84M | $386.53M | $397.97M | $433.85M | $383.60M | $388.57M | $386.35M | $342.96M | $368.59M | $358.63M | $378.33M | $271.12M | $435.73M | $326.03M | $351.79M | $387.28M |
| High Forecast | $397.08M | $388.48M | $409.22M | $400.13M | $402.94M | $389.01M | $407.16M | $520.61M | $393.50M | $395.19M | $395.28M | $411.55M | $377.11M | $430.36M | $378.33M | $325.34M | $522.87M | $391.23M | $422.14M | $396.51M |
| Low Forecast | $381.12M | $372.87M | $392.78M | $384.06M | $386.75M | $381.58M | $390.80M | $347.08M | $376.17M | $384.62M | $379.40M | $274.37M | $361.96M | $286.90M | $378.33M | $216.89M | $348.58M | $260.82M | $281.43M | $379.26M |
| Surprise % | - | - | - | - | - | - | - | - | 1.22% | 0.00% | 0.00% | 1.27% | 1.28% | 1.23% | - | 1.37% | 1.11% | 1.19% | 1.18% | 0.99% |
Organon's average Quarter SG&A projection for Mar 24 is $433.85M, based on 1 Wall Street analysts, with a range of $347.08M to $520.61M. The forecast indicates a -7.50% fall compared to OGN last annual SG&A of $469.00M (Dec 23).
Organon EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $2.13 | - | - | $0.70 | $0.42 | $0.89 | - | $1.37 | $0.80 | $1.27 | $1.68 | $1.58 |
| Avg Forecast | $1.10 | $1.04 | $1.14 | $1.10 | $1.03 | $1.00 | $1.08 | $0.98 | $0.81 | $1.05 | $0.97 | $1.17 | $0.92 | $1.10 | $1.17 | $1.30 | $1.24 | $1.44 | $1.42 | $1.73 |
| High Forecast | $1.14 | $1.07 | $1.17 | $1.13 | $1.06 | $1.04 | $1.11 | $1.01 | $1.08 | $1.08 | $1.00 | $1.20 | $0.95 | $1.13 | $1.17 | $1.34 | $1.28 | $1.48 | $1.46 | $1.78 |
| Low Forecast | $1.08 | $1.01 | $1.11 | $1.07 | $1.01 | $0.96 | $1.05 | $0.95 | $0.69 | $1.02 | $0.95 | $1.14 | $0.90 | $1.08 | $1.17 | $1.27 | $1.21 | $1.40 | $1.38 | $1.68 |
| Surprise % | - | - | - | - | - | - | - | - | 2.63% | 0.00% | 0.00% | 0.60% | 0.46% | 0.81% | - | 1.05% | 0.64% | 0.88% | 1.19% | 0.91% |
According to 1 Wall Street analysts, Organon's projected average Quarter EPS for Mar 24 is $0.98, with a low estimate of $0.95 and a high estimate of $1.01. This represents a -54.09% decrease compared to OGN previous annual EPS of $2.13 (Dec 23).
Organon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.83 | $46.29 | 55.18% | Hold |
| BIIB | Biogen | $198.21 | $291.45 | 47.04% | Buy |
| BMY | Bristol-Myers Squibb Company | $49.49 | $65.43 | 32.21% | Hold |
| OGN | Organon | $20.55 | $24.00 | 16.79% | Buy |
| MRK | Merck | $118.29 | $127.74 | 7.99% | Buy |
| AZN | AstraZeneca | $78.53 | $84.33 | 7.39% | Buy |
| JNJ | Johnson & Johnson | $167.07 | $176.29 | 5.52% | Buy |
| SNY | Sanofi | $56.91 | $57.36 | 0.79% | Buy |
| NVS | Novartis | $115.70 | $115.67 | -0.03% | Hold |
| GILD | Gilead Sciences | $83.05 | $80.00 | -3.67% | Buy |
| ABBV | AbbVie | $193.45 | $167.54 | -13.39% | Buy |
| AMGN | Amgen | $332.80 | $286.95 | -13.78% | Buy |
| LLY | Eli Lilly and Company | $906.18 | $753.65 | -16.83% | Buy |
OGN Forecast FAQ
Is Organon a good buy?
Yes, according to 3 Wall Street analysts, Organon (OGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of OGN's total ratings.
What is OGN's price target?
Organon (OGN) average price target is $24 with a range of $24 to $24, implying a 16.79% from its last price of $20.55. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Organon stock go up soon?
According to Wall Street analysts' prediction for OGN stock, the company can go up by 16.79% (from the last price of $20.55 to the average price target of $24), up by 16.79% based on the highest stock price target, and up by 16.79% based on the lowest stock price target.
Can Organon stock reach $30?
OGN's average twelve months analyst stock price target of $24 does not support the claim that Organon can reach $30 in the near future.
What are Organon's analysts' financial forecasts?
Organon's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.34B (high $6.46B, low $6.23B), average EBITDA is $2.33B (high $2.5B, low $2.17B), average net income is $1.21B (high $1.32B, low $1.1B), average SG&A $1.61B (high $1.72B, low $1.51B), and average EPS is $4.08 (high $4.21, low $3.97). OGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.32B (high $6.46B, low $6.2B), average EBITDA is $2.17B (high $2.22B, low $2.13B), average net income is $1.13B (high $1.16B, low $1.1B), average SG&A $1.56B (high $1.59B, low $1.53B), and average EPS is $4.37 (high $4.51, low $4.27).
Did the OGN's actual financial results beat the analysts' financial forecasts?
Based on Organon's last annual report (Dec 2023), the company's revenue was $6.26B, beating the average analysts forecast of $6.24B by 0.43%. Apple's EBITDA was $1.55B, missing the average prediction of $2.16B by -28.11%. The company's net income was $1.02B, missing the average estimation of $1.05B by -2.99%. Apple's SG&A was $1.89B, beating the average forecast of $1.5B by 26.08%. Lastly, the company's EPS was $3.99, missing the average prediction of $4 by -0.24%. In terms of the last quarterly report (Dec 2023), Organon's revenue was $1.6B, beating the average analysts' forecast of $1.55B by 2.83%. The company's EBITDA was $370M, missing the average prediction of $534.05M by -30.72%. Organon's net income was $546M, beating the average estimation of $209.72M by 160.34%. The company's SG&A was $469M, beating the average forecast of $383.6M by 22.26%. Lastly, the company's EPS was $2.13, beating the average prediction of $0.811 by 162.64%